PortfoliosLab logoPortfoliosLab logo
MIMI vs. CHRS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MIMI vs. CHRS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mint Incorporation Ltd (MIMI) and Coherus BioSciences, Inc. (CHRS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MIMI achieves a -7.67% return, which is significantly lower than CHRS's 4.23% return.


MIMI

1D
-3.82%
1M
-24.11%
YTD
-7.67%
6M
-28.37%
1Y
-96.07%
3Y*
5Y*
10Y*

CHRS

1D
0.00%
1M
-8.07%
YTD
4.23%
6M
5.71%
1Y
98.07%
3Y*
-28.15%
5Y*
-36.77%
10Y*
-20.84%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MIMI vs. CHRS - Yearly Performance Comparison


2026 (YTD)2025
MIMI
Mint Incorporation Ltd
-7.67%-93.18%
CHRS
Coherus BioSciences, Inc.
4.23%-5.96%

Correlation

The correlation between MIMI and CHRS is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.06

Correlation (All Time)
Calculated using the full available price history since Jan 10, 2025

-0.03

Fundamentals

EPS

MIMI:

-$0.11

CHRS:

$1.52

PS Ratio

MIMI:

31.14

CHRS:

3.86

Total Revenue (TTM)

MIMI:

$2.22M

CHRS:

$46.88M

Gross Profit (TTM)

MIMI:

$328.32K

CHRS:

$23.41M

EBITDA (TTM)

MIMI:

-$2.88M

CHRS:

-$162.15M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MIMI vs. CHRS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MIMI
MIMI Risk / Return Rank: 1111
Overall Rank
MIMI Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
MIMI Sortino Ratio Rank: 1010
Sortino Ratio Rank
MIMI Omega Ratio Rank: 1010
Omega Ratio Rank
MIMI Calmar Ratio Rank: 22
Calmar Ratio Rank
MIMI Martin Ratio Rank: 1414
Martin Ratio Rank

CHRS
CHRS Risk / Return Rank: 7575
Overall Rank
CHRS Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
CHRS Sortino Ratio Rank: 7575
Sortino Ratio Rank
CHRS Omega Ratio Rank: 7272
Omega Ratio Rank
CHRS Calmar Ratio Rank: 7777
Calmar Ratio Rank
CHRS Martin Ratio Rank: 7272
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MIMI vs. CHRS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Mint Incorporation Ltd (MIMI) and Coherus BioSciences, Inc. (CHRS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MIMICHRSDifference
Sharpe ratioReturn per unit of total volatility

-1.69

Sortino ratioReturn per unit of downside risk

-3.11

Omega ratioGain probability vs. loss probability

0.85

1.23

-0.38

Calmar ratioReturn relative to maximum drawdown

-0.98

2.15

-3.14

Martin ratioReturn relative to average drawdown

-1.24

4.08

-5.32

MIMI vs. CHRS - Sharpe Ratio Comparison

The current MIMI Sharpe Ratio is -0.48, which is lower than the CHRS Sharpe Ratio of 1.21. The chart below compares the historical Sharpe Ratios of MIMI and CHRS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MIMI vs. CHRS - Drawdown Comparison

The maximum MIMI drawdown since its inception was -97.68%, roughly equal to the maximum CHRS drawdown of -98.21%. Use the drawdown chart below to compare losses from any high point for MIMI and CHRS.


Loading charts...

Drawdown Indicators


MIMICHRSDifference

Max Drawdown

Largest peak-to-trough decline

-97.68%

-98.21%

+0.53%

Max Drawdown (1Y)

Largest decline over 1 year

-97.68%

-45.82%

-51.86%

Max Drawdown (3Y)

Largest decline over 3 years

-87.71%

Max Drawdown (5Y)

Largest decline over 5 years

-96.47%

Max Drawdown (10Y)

Largest decline over 10 years

-97.88%

Current Drawdown

Current decline from peak

-97.42%

-96.05%

-1.37%

Average Drawdown

Average peak-to-trough decline

-52.61%

-63.60%

+10.99%

Ulcer Index

Depth and duration of drawdowns from previous peaks

77.63%

24.10%

+53.53%

Volatility

MIMI vs. CHRS - Volatility Comparison

Mint Incorporation Ltd (MIMI) has a higher volatility of 28.27% compared to Coherus BioSciences, Inc. (CHRS) at 16.95%. This indicates that MIMI's price experiences larger fluctuations and is considered to be riskier than CHRS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MIMICHRSDifference

Volatility (1M)

Calculated over the trailing 1-month period

28.27%

16.95%

+11.32%

Volatility (6M)

Calculated over the trailing 6-month period

130.14%

59.73%

+70.41%

Volatility (1Y)

Calculated over the trailing 1-year period

200.11%

81.94%

+118.17%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

172.75%

84.83%

+87.92%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

172.75%

74.98%

+97.77%

Dividends

MIMI vs. CHRS - Dividend Comparison

Neither MIMI nor CHRS has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

MIMI vs. CHRS - Financials Comparison

This section allows you to compare key financial metrics between Mint Incorporation Ltd and Coherus BioSciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
126.51K
12.31M
(MIMI) Total Revenue
(CHRS) Total Revenue
Values in USD except per share items

Frequently Asked Questions


MIMI and CHRS have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MIMI has higher volatility (28.27%) compared to CHRS (16.95%). In terms of maximum drawdown, MIMI dropped -97.68% vs CHRS's -98.21%.

CHRS currently has the higher Sharpe Ratio (1.21 vs -0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MIMI and CHRS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer